¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀå : ÀǾàǰ À¯Çüº°, ¿ëµµº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº° - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2024-2033³â)
Cytotoxic Drug Market By Drug Type , By Application By Route of Administration By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
»óǰÄÚµå : 1566974
¸®¼­Ä¡»ç : Allied Market Research
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 245 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,425 £Ü 6,402,000
PDF (Business License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 2¸í ÀÌ»óÀÌ ÀÌ¿ëÇÒ °æ¿ì, Ãß°¡ ¿ä±ÝÀ» ÁöºÒÇÏ¿© ¶óÀ̼±½º ¾÷±×·¹À̵å·Î ÃÖ´ë 5¸í±îÁö ÀÌ¿ë °¡´ÉÇÕ´Ï´Ù.
US $ 7,412 £Ü 10,724,000
PDF (Enterprise User License) & Excel (Data Pack) & Free Update help
PDF º¸°í¼­ ¹× Excel µ¥ÀÌÅ͸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. º¸°í¼­ ¾÷µ¥ÀÌÆ® ¼­ºñ½º°¡ ¹«·á·Î Á¦°øµË´Ï´Ù.


Çѱ۸ñÂ÷

¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀåÀº 2023³â 158¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2033³â°£ ¿¬Æò±Õ 2.1% ¼ºÀåÇÏ¿© 2033³â¿¡´Â 195¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼Æ÷µ¶¼º ¾à¹°Àº DNA¿¡ Á÷Á¢ ÀÛ¿ëÇϰųª ´Ü¹éÁú »ýÇÕ¼ºÀ» ¾ïÁ¦ÇÏ¿© ¾Ï¼¼Æ÷ÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â È­Çпä¹ýÁ¦ÀÔ´Ï´Ù. ±×·¯³ª °ñ¼ö, ¼ÒÈ­°ü, ¸ð³¶ µî ÀÚÁÖ ºÐ¿­ÇÏ´Â °Ç°­ÇÑ ¼¼Æ÷¿¡µµ ÀÛ¿ëÇϱ⠶§¹®¿¡ ±× »ç¿ëÀº Á¾Á¾ ½É°¢ÇÑ ºÎÀÛ¿ëÀ» µ¿¹ÝÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¿¡µµ ºÒ±¸ÇÏ°í ¼¼Æ÷µ¶¼º ¾à¹°Àº ¿©ÀüÈ÷ ´Ù¾çÇÑ ¾Ï Ä¡·á¿¡ ÇʼöÀûÀ̸ç, »ýÁ¸À² Çâ»ó°ú Áúº´ °ü¸® °³¼±¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀåÀÇ ¼ºÀåÀº ¾ÏÀÇ ½É°¢ÇÑ À¯º´·ü Áõ°¡°¡ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¾ÏÀº »ç¸Á ¿øÀÎ 1À§À̸ç 2020³â¿¡´Â ¾à 1,000¸¸ ¸íÀÌ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³ëÀÎ Àα¸ÀÇ ±Þ°ÝÇÑ Áõ°¡µµ ¼¼°è ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ³ë³âÃþÀÌ ¾Ï¿¡ °É¸®±â ½±´Ù´Â »ç½ÇÀÌ ¾Ï Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ¾ÏÀÇ Á¶±â ¹ß°ß°ú Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä µ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ¾Ï Çùȸ´Â Á¶±â Áø´ÜÀ» ¹ÞÀº ¾Ï ȯÀÚÀÇ 5³â »ýÁ¸À²ÀÌ 90%ÀÎ ¹Ý¸é, Èıâ Áø´ÜÀ» ¹ÞÀº ȯÀÚÀÇ 5³â »ýÁ¸À²Àº 20%¿¡ ºÒ°úÇÏ´Ù´Â Á¡À» °­Á¶Çϸç Á¶±â ¹ß°ß°ú ±×¿¡ µû¸¥ Ä¡·á¿¡¼­ ¼¼Æ÷µ¶¼º ¾à¹°ÀÇ »ç¿ëÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ È¯ÀÚ °³°³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃá Ç¥Àû ¼¼Æ÷µ¶¼º Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °æ±¸¿ë ¼¼Æ÷µ¶¼º ¾à¹°Àº ȯÀÚÀÇ ¼øÀÀµµ¿Í »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ÆíÀǼº°ú Åõ¿©ÀÇ ¿ëÀ̼ºÀ¸·Î ÀÎÇØ ³ôÀº ÁöÁö¸¦ ¹Þ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¸Þ½º²¨¿ò, Å»¸ð, °ñ¼ö ¾ïÁ¦¿Í °°Àº ¼¼Æ÷µ¶¼º ¾à¹°°ú °ü·ÃµÈ ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ »ç¿ëÀÌ Á¦Çѵǰí ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°è ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç¥ÀûÄ¡·áÁ¦, ¸é¿ªÄ¡·áÁ¦, ±âŸ Çõ½ÅÀûÀÎ ¾Ï Ä¡·á¹ý µî º¸´Ù È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ±âÁ¸ ¼¼Æ÷µ¶¼º ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä°¡ °¨¼ÒÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀåÀÇ ÁÖ¿ä ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¹Ý¸é, ¼¼Æ÷µ¶¼º ¾à¹°ÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ ¾à¹° Á¦Çü ¹× ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Çõ½ÅÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ÃÖ±Ù ¿¬±¸¿¡ µû¸£¸é ¸®Æ÷Á» µ¶¼Ò·çºñ½Å°ú °°Àº ¼¼Æ÷µ¶¼º ¾à¹°ÀÇ »õ·Î¿î Á¦ÇüÀÌ ºÎÀÛ¿ëÀ» ÁÙÀ̰í ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ ÀÌ·¯ÇÑ Ã·´Ü Á¦Á¦´Â Á¾¾ç ºÎÀ§·ÎÀÇ ¾à¹° Àü´ÞÀ» 30-40% Çâ»ó½Ãų ¼ö ÀÖ´Ù´Â °ÍÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù.

¼¼°è ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀåÀº ¾à¹° À¯Çü, ¿ëµµ, Åõ¿© °æ·Î, À¯Åë ä³Î, Áö¿ªÀ¸·Î ºÐ·ùµË´Ï´Ù. ¾à¹° À¯ÇüÀº ¾ËųȭÁ¦, Ç×Á¾¾ç Ç×»ýÁ¦, ´ë»ç ±æÇ×Á¦, ½Ä¹°¼º ¾ËÄ®·ÎÀ̵å, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ¿ëµµº°·Î´Â À¯¹æ¾Ï, Àü¸³¼±¾Ï, Æó¾Ï, ÃéÀå¾Ï, ±âŸ·Î ºÐ·ùµË´Ï´Ù. Åõ¿© °æ·Î¿¡ µû¶ó °æ±¸Á¦¿Í ºñ°æ±¸Á¦·Î ³ª´¹´Ï´Ù. À¯Åë ä³Î¿¡ µû¶ó º´¿ø ¾à±¹, µå·°½ºÅä¾î ¹× ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ Á¦°ø¾÷ü·Î ¼¼ºÐÈ­µË´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ºÐ¼®µË´Ï´Ù.

ÁÖ¿ä Á¶»ç °á°ú

¾à¹° À¯Çüº°·Î´Â 2033³â ´ë»ç ±æÇ×Á¦ ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿ëµµº°·Î´Â À¯¹æ¾ÏÀÌ ¿¹Ãø ±â°£ µ¿¾È ÁÖ¿ä ºÎ¹®À¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Åõ¿© °æ·Îº°·Î´Â °æ±¸Á¦°¡ ÇâÈÄ ¸î ³âµ¿¾È °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯Åë ä³Îº°·Î´Â º´¿ø ¾à±¹ ºÎ¹®ÀÌ °¡±î¿î ¹Ì·¡¿¡ ¼¼°è ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀåÀ» ÁÖµµÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀåÀÇ ÁÖ¿ä ÁÖÁÖÀ̸ç, ¿¹Ãø ±â°£ µ¿¾È ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­ÀÇ Ä¿½ºÅ͸¶ÀÌ¡ÀÌ °¡´ÉÇÕ´Ï´Ù(º°µµÀÇ ºñ¿ë°ú ÀÏÁ¤ÀÌ ÇÊ¿äÇÕ´Ï´Ù).

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ±¸µµ

Á¦4Àå ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀå : ¾à À¯Çüº°

Á¦5Àå ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀå : ¿ëµµº°

Á¦6Àå ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀå : Åõ¿© °æ·Îº°

Á¦7Àå ÀÓ»ó µ¶¼º¾à½ÃÀå : À¯Åë ä³Îº°

Á¦8Àå ¼¼Æ÷µ¶¼º ¾à¹° ½ÃÀå : Áö¿ªº°

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The cytotoxic drug market was valued at $15.8 billion in 2023, and is projected to reach $19.5 billion by 2033, growing at a CAGR of 2.1% from 2024 to 2033.

Cytotoxic drugs are chemotherapeutic agents that inhibit the growth of cancer cells by acting directly on the DNA or interfering with the biosynthesis of proteins. However, because they also affect healthy cells that divide frequently, such as those in the bone marrow, digestive tract, and hair follicles, their use is often accompanied by significant side effects. Despite these challenges, cytotoxic drugs remain essential in the treatment of various cancers, contributing to improved survival rates and better management of the disease.

The growth of the global cytotoxic drug market is majorly driven by alarming increase prevalence of cancer. According to the World Health Organization, cancer is the leading cause of death, and accounted for approximately 10 million deaths in 2020, thus fueling the demand for effective chemotherapy treatments, including cytotoxic drugs. Moreover, surge in geriatric population significantly contributes toward the growth of the global market. This is attributed to the fact that aged individuals are highly susceptible to cancer, leading to higher demand for cancer treatments. Furthermore, rise in awareness about early detection and treatment of cancer acts as the key driving force of the market. The American Cancer Society highlights that the five-year survival rate for cancer patients diagnosed at an early stage is 90%, compared to 20% for those diagnosed at a later stage, thereby highlighting the importance of early detection and the consequent use of cytotoxic drugs in treatment. Rise in emphasis on developing targeted cytotoxic therapies tailored to individual patients' genetic profiles to improve treatment efficacy and minimize side effects is further propelling the market growth. In addition, oral cytotoxic drugs are gaining high traction due to their convenience and ease of administration, allowing for better patient compliance and quality of life, thus augmenting the market growth. However, adverse effects associated with cytotoxic drugs, such as nausea, hair loss, and bone marrow suppression, limit their use, which hampers the growth of the global market. In addition, rise in awareness about more effective therapies such as targeted therapies, immunotherapies, and other innovative cancer treatments potentially reduce the demand for traditional cytotoxic drugs, which acts as the key deterrent factor of the market. On the contrary, innovations in drug formulation and delivery systems to enhance the efficacy and safety of cytotoxic drugs are expected to offer lucrative opportunities for the growth of the global market during the forecast period. For instance, recent studies have shown that new formulations of cytotoxic drugs, such as liposomal doxorubicin, can reduce side effects and improve patient outcomes. Clinical trials have demonstrated that these advanced formulations can enhance drug delivery to tumor sites by 30-40%.

The global cytotoxic drug market is segmented into drug type, application, route of administration, distribution channel, and region. On the basis of the drug type, the market is segregated into alkylating agents, antitumor antibiotics, antimetabolites, plant alkaloids, and others. As per application, it is classified into breast cancer, prostate cancer, lung cancer, pancreatic cancer, and others. By route of administration, it is bifurcated into oral and parenteral. According to distribution channel, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By drug type, the antimetabolites segment is expected to dominate the market by 2033.

On the basis of application, breast cancer is anticipated to emerge as a leading segment during the forecast period.

Depending on route of administration, the oral segment is projected to exhibit the highest growth in the coming years.

As per distribution channel, the hospital pharmacies segment is likely to lead the lobal cytotoxic drug market in the near future.

Region wise, North America was the major shareholder in the cytotoxic drug market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global cytotoxic drug market include Baxter, Cipla Ltd, Eli Lilly and Company, Fresenius Kabi AG, Johnson & Johnson, Novartis AG, Viatris Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Key Market Segments

By Drug Type

By Application

By Route Of Administration

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET LANDSCAPE

CHAPTER 4: CYTOTOXIC DRUG MARKET, BY DRUG TYPE

CHAPTER 5: CYTOTOXIC DRUG MARKET, BY APPLICATION

CHAPTER 6: CYTOTOXIC DRUG MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 7: CYTOTOXIC DRUG MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 8: CYTOTOXIC DRUG MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â